-
公开(公告)号：EP4393509A1
公开(公告)日：2024-07-03
申请号：EP22861452.5
申请日：2022-08-26
发明人： KATSUMI Keiko , OYA Junpei , ISHII Keisuke , SAKAMOTO Aya
IPC分类号： A61K45/00 , A61K39/395 , A61P35/00 , A61P39/06 , A61P43/00
CPC分类号： A61P43/00 , A61K39/395 , A61K45/00 , A61P35/00 , A61P39/06
摘要： It is an object of the present invention to provide an ROS production-enhancing agent. According to the present invention, an ROS production-enhancing agent, comprising a substance that recognizes a transferrin receptor, is provided.
-
公开(公告)号：EP4066858A1
公开(公告)日：2022-10-05
申请号：EP20892360.7
申请日：2020-11-27
发明人： NOMURA Fumiko , MATSUURA Tadashi , ZHANG Lilin , AIKAWA Yoichi , ASAO Takayuki , YOKOBORI Takehiko
摘要： It is an object of the present invention to provide a therapeutic drug for carcinomatous peritonitis. According to the present invention, a therapeutic drug for carcinomatous peritonitis which comprises an antibody which recognizes a transferrin receptor, is provided.
-
公开(公告)号：EP2918603B1
公开(公告)日：2018-08-29
申请号：EP13853637.0
申请日：2013-11-08
发明人： KUROSAWA, Yoshikazu , MORISHITA, Kazuhiro , ZHANG, Lilin , KUROSAWA, Gene , MITOMO, Katsuyuki , SUDO, Yukio , NOMURA, Fumiko , UKAI, Yoshinori
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , A61P35/02 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/08
CPC分类号： C07K16/2881 , A61K2039/505 , C07K16/30 , C07K2317/14 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/92
摘要： The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1,2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.
-
公开(公告)号：EP2634194B1
公开(公告)日：2018-08-15
申请号：EP11836461.1
申请日：2011-10-28
发明人： ISHII, Keisuke , KATSUMI, Keiko , MATSUURA, Tadashi , SUDO, Yukio , MITOMO, Katsuyuki , KOUDA, Katsushi
CPC分类号： C07K16/18 , A61K47/6849 , A61K2039/505 , C07K16/2896 , C07K2317/77
摘要： It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.
-
5.发明公开
公开(公告)号：EP3037533A4
公开(公告)日：2017-07-05
申请号：EP14838190
申请日：2014-08-20
申请人： FUJITA HEALTH UNIV , THE RES FOUND FOR MICROBIAL DISEASES OF OSAKA UNIV , PERSEUS PROTEOMICS INC
IPC分类号： C12N15/09 , A61K39/395 , A61P31/16 , C07K16/10 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08
CPC分类号： C07K16/1018 , C07K2317/76
摘要： It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).
摘要翻译： 本发明的目的是提供对流感病毒具有高结合活性和高中和活性的新型抗体。 本发明提供了中和H1流感病毒和/或H5流感病毒的抗体，其中所述抗体具有重链可变区，所述重链可变区具有由确定的重链第一互补决定区（VH CDR1），确定的重链 第二互补决定区（VH CDR2）和确定的重链第三互补决定区（VH CDR3）;以及轻链可变区，其具有由确定的轻链第二互补决定区（VL CDR2）组成的CDR和限定的重链第三互补决定区 轻链第三互补决定区（VL CDR3）。
-
公开(公告)号：EP2634194A4
公开(公告)日：2014-05-28
申请号：EP11836461
申请日：2011-10-28
发明人： ISHII KEISUKE , KATSUMI KEIKO , MATSUURA TADASHI , SUDO YUKIO , MITOMO KATSUYUKI , KOUDA KATSUSHI
IPC分类号： C07K16/28 , A61K39/395 , A61K47/48 , A61P35/00 , C07K16/46 , C12N5/10 , C12N15/02 , C12P21/08
CPC分类号： C07K16/18 , A61K47/48561 , A61K47/6849 , A61K2039/505 , C07K16/2896 , C07K2317/77
摘要： It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.
-
7.发明公开AGENT FOR PREDICTING AND JUDGING THE RECURRENCE AFTER TREATING LIVER CANCER 审中-公开MEANS治疗后预测与评价复发肝癌的人
公开(公告)号：EP1742061A4
公开(公告)日：2007-11-21
申请号：EP05736601
申请日：2005-04-28
发明人： WATANABE KIYOTAKA , OHNISHI SHIN , ABURATANI HIROYUKI , MIDORIKAWA YUTAKA , HIPPO YOSHITAKA , IWANARI HIROKO , TOKITA SUSUMU , SATOH HIROKAZU
IPC分类号： G01N33/574
CPC分类号： G01N33/57492 , G01N33/57438
摘要： It is intended to provide a method of predicting the recurrence after treating liver cancer. A method of predicting the recurrence after treating liver cancer characterized by assaying GPC3 in a test sample with the use of anti-GPC3 antibody.
-
8.发明公开CANCER DIAGNOSIS AND TREATMENT USING ANTI-ROBO1 ANTIBODY 有权KREBSDIAGNOSE UND BEHANDLUNG UNTER VERWENDUNG EINES ANTI-ROBO1-ANTIKÖRPERS
公开(公告)号：EP1744162A4
公开(公告)日：2007-07-11
申请号：EP05728904
申请日：2005-03-31
发明人： ABURATANI HIROYUKI , HIPPO YOSHITAKA , WATANABE AKIRA , FUKAYAMA MASASHI , ITO YUKIO , ARAI MASAHIRO , ITO HIROTAKA , OHTOMO TOSHIHIKO , FUNAHASHI SHIN-ICHI , KINOSHITA YASUKO
IPC分类号： G01N33/574 , C07K16/30 , C12N15/02 , C12N15/09 , G01N33/576
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/30 , C07K16/303 , C07K2317/73 , C07K2317/732 , C07K2317/734 , G01N33/57438 , G01N33/57488 , G01N33/576
摘要： A method of cancer diagnosis characterized in that ROBO1 protein is detected. Further, there is disclosed a method of treating diseases attributed to abnormal cell growth, comprising administering an antibody capable of binding to ROBO1, and are disclosed, comprising an antibody capable of binding to ROBO1 as an active ingredient, a pharmaceutical composition, cytostatic agent and anticancer agent. Still further, there is disclosed a method of inhibiting the growth of ROBO1 expression cells or method of inducing cytotoxicity in ROBO1 expression cells, comprising bringing an antibody capable of binding to ROBO1 into contact with ROBO1 expression cells. Moreover, there is disclosed a method of monitoring the intensification of hepatitis severity, comprising detection of ROBO1 protein.
摘要翻译： 公开了一种诊断癌症的方法，包括检测ROBO1蛋白。 此外，用于治疗由异常细胞生长引起的疾病的方法包括施用与ROBO1结合的抗体，以及药物组合物，细胞生长抑制剂和抗癌剂，其包含结合ROBO1作为有效成分的抗体的方法， 披露。 此外，公开了通过使ROBO1表达细胞与与ROBO1结合的抗体接触来抑制ROBO1表达细胞中的细胞损伤的方法和抑制ROBO1表达细胞的生长的方法。 此外，公开了通过检测ROB01蛋白来监测肝炎进展的方法。
-
公开(公告)号：EP4458859A2
公开(公告)日：2024-11-06
申请号：EP24201291.2
申请日：2012-04-04
发明人： ISHII, Keisuke , MITOMO, Katsuyuki , KOUDA, Katsushi , NOMURA, Fumiko , KAYUKAWA, Yoko , MATSUURA, Tadashi
IPC分类号： C07K16/28
摘要： It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.
-
公开(公告)号：EP2399993B1
公开(公告)日：2017-09-20
申请号：EP10743584.4
申请日：2010-02-19
CPC分类号： B82Y5/00 , A61K47/6898 , C07K14/36 , C07K16/14 , C07K2317/56 , C07K2317/622 , C07K2317/92
-
-
-
-
-
-
-
-
-
搜索结果
71 条记录 (耗时 0.014 秒)
